127892-81-3

Basic information

• Product Name: 4-Pyrimidinol,2-phenyl-(9CI)
• Synonyms: 4-Pyrimidinol,2-phenyl-(9CI)
• CAS NO: 127892-81-3
• Molecular Formula: C10H8N2O
• Molecular Weight: 172.19
• Product Categories: QUINAZOLINE
• Mol File: 127892-81-3.mol

Chemical Properties

• Boiling Point: 236.3±23.0 °C(Predicted)
• Appearance: /
• Density: 1.233±0.06 g/cm3(Predicted)
• PKA: 7.86±0.10(Predicted)
• CAS DataBase Reference: 4-Pyrimidinol,2-phenyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyrimidinol,2-phenyl-(9CI)(127892-81-3)
• EPA Substance Registry System: 4-Pyrimidinol,2-phenyl-(9CI)(127892-81-3)

Safety Data

• Hazardous Substances Data: 127892-81-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
4-Pyrimidinol,2-phenyl-(9CI) is used as a key intermediate in the synthesis of various pharmaceuticals for the treatment of different diseases. Its unique structure allows for the development of new drugs with improved efficacy and reduced side effects.
Used in Medicinal Chemistry Research:
4-Pyrimidinol,2-phenyl-(9CI) is used as a research compound in medicinal chemistry to study its potential interactions with biological targets and to understand its mechanism of action. This research can lead to the discovery of new therapeutic agents and a better understanding of disease pathways.
Used in Industrial Processes:
4-Pyrimidinol,2-phenyl-(9CI) may be used in various industrial processes, such as the synthesis of other chemical compounds or as a catalyst in certain chemical reactions. Its specific applications in this field are still being explored and researched.

Upstream product

• 618-39-3 benzamidin 
• 623-47-2 propynoic acid ethyl ester 
• 15934-46-0 benzamidene hydrochloride 

Downstream Products

• 1266479-98-4 4,5-dibromo-2-phenylpyrimidine 
• 1266480-03-8 tert-butyl 5-cyclopropyl-3-(5-iodo-2-phenylpyrimidin-4-ylamino)-1H-pyrazole-1-carboxylate 
• 1266480-01-6 4-bromo-5-iodo-2-phenylpyrimidine 
• 1266480-02-7 N-(5-cyclopropyl-1H-pyrazol-3-yl)-5-iodo-2-phenylpyrimidin-4-amine 
• 1266476-75-8 5-bromo-N-(5-cyclopropyl-2H-pyrazol-3-yl)-2-phenyl-pyrimidin-4-amine 

Relevant articles and documents

Discovery of wtRET and V804MRET Inhibitors: From Hit to Lead

Oncogenic activation of RET kinase has been found in several neoplastic diseases, like medullary thyroid carcinoma, multiple endocrine neoplasia, papillary thyroid carcinoma, and non-small-cell lung cancer. Currently approved RET inhibitors were not originally designed to be RET inhibitors, and their potency against RET kinase has not been optimized. Hence, novel compounds able to inhibit both wild-type RET (wtRET) and its mutants (e.g., V804MRET) are needed. Herein we present the development and the preliminary evaluation of a new sub-micromolar wtRET/V804MRET inhibitor, N-(2-fluoro-5-trifluoromethylphenyl)-N′-{4′-[(2′′-benzamido)pyridin-4′′-ylamino]phenyl}urea (69), endowed with a 4-anilinopyridine structure, starting from our previously identified 4-anilinopyrimidine hit compound. Profiling against a panel of kinases indicated 69 as a multi cKIT/wtRET/V804MRET inhibitor.

PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS

The present invention relates to compounds II useful as inhibitors of treating tuberculosis. The invention also provides processes for preparing compounds of the invention.